| Title | Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. | | Author(s) | Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, Shults C, Masliah E | | Institution | Departments of aNeurosciences bPathology, University of California San Diego, School of Medicine, La Jolla, California, USA. | | Source | Neuroreport 2008 Aug 27; 19(13):1271-6. | | Abstract | Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by oligodendrocytic cytoplasmic inclusions containing abnormally aggregated alpha-synuclein. This aggregation has been linked to the neurodegeneration observed in MSA. Current MSA treatments are aimed at controlling symptoms rather than tackling the underlying cause of neurodegeneration. This study investigates the ability of the antibiotic rifampicin to reduce alpha-synuclein aggregation and the associated neurodegeneration in a transgenic mouse model of MSA. We report a reduction in monomeric and oligomeric alpha-synuclein and a reduction in phosphorylated alpha-synuclein (S129) upon rifampicin treatment. This reduction in alpha-synuclein aggregation was accompanied by reduced neurodegeneration. On the basis of its anti-aggregenic properties, we conclude that rifampicin may have therapeutic potential for MSA. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 18695506 |
|
